Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
04.03. | Evaxion Biotech: Evaxion to present at numerous upcoming conferences | 213 | GlobeNewswire (Europe) | Evaxion will provide company and scientific updates at conferences in both the US and Europe during the coming weeks and months
COPENHAGEN, Denmark, March 4, 2025 - Evaxion Biotech A/S (NASDAQ:... ► Artikel lesen | |
04.03. | Evaxion Biotech A/S - 6-K, Report of foreign issuer | - | SEC Filings | ||
25.02. | Evaxion Biotech: Evaxion extends phase 2 trial with personalized cancer vaccine EVX-01 to further enhance clinical data package | 298 | GlobeNewswire (Europe) | Originally planned as a two-year study, the trial has been extended by an additional year to collect three-year clinical outcome data The additional third year of EVX-01 dosing may provide further insights... ► Artikel lesen | |
25.02. | Evaxion Biotech A/S - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
14.02. | Evaxion re-establishes compliance with Nasdaq minimum stockholders' equity requirement | 2 | Seeking Alpha | ||
EVAXION BIOTECH Aktie jetzt für 0€ handeln | |||||
14.02. | Evaxion secures Nasdaq listing with equity boost | 4 | Investing.com | ||
14.02. | Evaxion Biotech: Nasdaq confirms Evaxion is fully compliant, withdraws delisting determination | 291 | GlobeNewswire (Europe) | Evaxion will remain listed on Nasdaq after successfully evidencing compliance with the Nasdaq minimum stockholders' equity requirement Evaxion has restored its equity above the minimum requirement through... ► Artikel lesen | |
12.02. | Evaxion Biotech A/S - 6-K, Report of foreign issuer | - | SEC Filings | ||
31.01. | Evaxion Biotech: Evaxion announces closing of $10.8 million public offering | 330 | GlobeNewswire (Europe) | COPENHAGEN, Denmark, January 31, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology powered vaccines, today announced the... ► Artikel lesen | |
30.01. | Evaxion Biotech: Evaxion announces pricing of $10.8 million public offering | 322 | GlobeNewswire (Europe) | COPENHAGEN, Denmark, January 30, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology powered vaccines, today announced the... ► Artikel lesen | |
28.01. | Evaxion Biotech A/S - F-1/A, Registration statement for certain foreign private issuers | - | SEC Filings | ||
28.01. | Evaxion granted 180-day compliance extension by Nasdaq | 3 | Seeking Alpha | ||
28.01. | Evaxion Biotech: Evaxion granted 180-day compliance extension by Nasdaq as it restores equity above minimum requirement | 270 | GlobeNewswire (Europe) | Following a constructive Nasdaq hearing panel on January 7, 2025, Evaxion has been granted a 180-day extension in relation to the Nasdaq minimum equity requirementEvaxion has currently restored its... ► Artikel lesen | |
27.01. | Evaxion Biotech A/S - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
15.01. | Evaxion Biotech Completes Dosing In Phase 2 Trial For Personalized Cancer Vaccine EVX-01 | 1 | RTTNews | ||
15.01. | Evaxion Biotech: Evaxion completes dosing in phase 2 trial with personalized cancer vaccine EVX-01 | 376 | GlobeNewswire (Europe) | Trial remains on track for completion and data readout in the second half of 2025
COPENHAGEN, Denmark, January 15, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio... ► Artikel lesen | |
14.01. | Evaxion Biotech: Evaxion announces completion of ADS ratio change | 388 | GlobeNewswire (Europe) | COPENHAGEN, Denmark, January 14, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion" or the "Company"), a clinical-stage TechBio company specializing in developing AI-Immunology powered vaccines, today... ► Artikel lesen | |
14.01. | Evaxion Biotech A/S - 6-K, Report of foreign issuer | - | SEC Filings | ||
10.01. | Evaxion Biotech: Evaxion announces extension to January 14, 2025, of plan to implement ADS ratio change | 292 | GlobeNewswire (Europe) | COPENHAGEN, Denmark, January 10, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology powered vaccines, today announced that... ► Artikel lesen | |
07.01. | Evaxion Biotech A/S - 6-K, Report of foreign issuer | - | SEC Filings |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 94,70 | -3,42 % | Konkurrenz für Novo Nordisk, BioNTech und Co: Steigen diese Biotech-Aktien bald bis zu 250%? | Für Anleger verstecken sich in der Biotech-Branche viele Papiere mit sagenhaften Kurschancen. Gerade 2 Aktien mit einem Durchhänger versprechen hohe Gewinne in der Zukunft. Die Biotech-Branche bietet... ► Artikel lesen | |
EVOTEC | 6,380 | -3,26 % | EQS-News: Evotec SE: Evotec gibt wichtige Fortschritte in der Neurologie-Partnerschaft mit Bristol Myers Squibb bekannt | EQS-News: Evotec SE
/ Schlagwort(e): Sonstiges
Evotec gibt wichtige Fortschritte in der Neurologie-Partnerschaft mit Bristol Myers Squibb bekannt
04.03.2025 / 07:30 CET/CEST
Für... ► Artikel lesen | |
CUREVAC | 2,732 | +0,59 % | CureVac Aktie: Bange Momente voraus? | Biotech-Unternehmen verzeichnet trotz täglicher Kursverluste beachtliches Handelsvolumen - positive Quartalszahlen und signifikantes Umsatzwachstum bieten Perspektiven Die CureVac-Aktie zeigte am Handelstag... ► Artikel lesen | |
QIAGEN | 36,335 | -0,52 % | Qiagen NV-Aktie läuft heute schlechter (36,415 €) | Im Minus liegt aktuell das Wertpapier von Qiagen NV . Das Papier kostete zuletzt 36,42 Euro. Die Qiagen NV-Aktie verzeichnet gegenwärtig ein Minus von 1,29 Prozent. Sie hat sich um 48 Cent gegenüber... ► Artikel lesen | |
PAION | 0,014 | -17,65 % | Paion Aktie: Platzt am Montag die Bombe? Diese Neuigkeiten müssen Anleger dringend beachten! | ||
AMGEN | 301,35 | -0,61 % | Amgen-Aktie: Kursrallye oder Trendumkehr? | ||
NOVAVAX | 7,560 | +3,49 % | Novavax Aktie: Platzt am Montag die Bombe? Diese Neuigkeiten müssen Anleger dringend beachten! | ||
STRYKER | 338,60 | -0,70 % | Stryker Unveils Steri-Shield 8 Personal Protection System To Boost Safety, Comfort | WASHINGTON (dpa-AFX) - Stryker Corp. (SYK), a medical technology company, Tuesday announced that it has introduced the Steri-Shield 8 personal protection system, the latest addition to its personal... ► Artikel lesen | |
BIOGEN | 139,00 | -0,25 % | Decoding Biogen's Options Activity: What's the Big Picture? | ||
CRISPR THERAPEUTICS | 39,600 | 0,00 % | FY2027 Earnings Forecast for CRSP Issued By Zacks Research | ||
OCUGEN | 0,530 | +0,47 % | Ocugen Provides Business Update with Fourth Quarter and Full Year 2024 Financial Results | Reached an alignment with FDA on Phase 2/3 pivotal confirmatory clinical trial for OCU410ST for Stargardt disease potentially expediting clinical development by two to three yearsCompleted dosing... ► Artikel lesen | |
MAINZ BIOMED | 5,695 | -100,00 % | Mainz Biomed Aktie: Platzt am Montag die Bombe? Diese Neuigkeiten müssen Anleger dringend beachten! | ||
TEMPUS AI | 45,100 | 0,00 % | Tempus AI, Inc. (TEM): Among The Stocks With At Least $10 Million In Insider Sales Recently | ||
MINERALYS THERAPEUTICS | 16,200 | 0,00 % | Mineralys Therapeutics Aktie: Revolutionärer Fortschritt! | Die Aktie von Mineralys Therapeutics verzeichnete einen beeindruckenden Anstieg auf ein 52-Wochen-Hoch von 15,41 US-Dollar, nachdem das Unternehmen vielversprechende Ergebnisse aus seinen klinischen... ► Artikel lesen | |
BEAM THERAPEUTICS | 26,540 | 0,00 % | Beam Therapeutics Reprots Positive Initial Phase 1/2 Data For BEAM-302 In AATD | WASHINGTON (dpa-AFX) - Beam Therapeutics Inc. (BEAM) Monday reported positive initial data from its Phase 1/2 study of BEAM-302 for the treatment of alpha-1 antitrypsin deficiency (AATD).AATD... ► Artikel lesen |